Most Influential NATURE REVIEWS CLINICAL ONCOLOGY Papers
Nature Reviews Clinical Oncology is a peer-reviewed journal for oncologists. The journal was renamed from Nature Clinical Practice Oncology in April 2009. Paper Digest Team analyze all papers published on NATURE REVIEWS CLINICAL ONCOLOGY in the past years, and presents the 10 most influential papers for each year (based on when the paper became available online). This ranking list is automatically constructed based upon citations from both research papers and granted patents, and will be frequently updated to reflect the most recent changes. To find the most influential papers from other conferences/journals, visit Best Paper Digest page. Note: the most influential papers may or may not include the papers that won the best paper awards. (Last updated on: 2021-05-23)
If you do not want to miss any interesting academic paper, you are welcome to sign up our free daily paper digest service to get updates on new papers published in your area every day. To search for papers with highlights, related papers, patents, grants, experts and organizations, please visit our search console. You are also welcome to follow us on Twitter and Linkedin to get updated with new conference digests.
Paper Digest Team
team@paperdigest.org
TABLE 1: Most Influential NATURE REVIEWS CLINICAL ONCOLOGY Papers
| Year | Rank | Paper | Author(s) |
|---|---|---|---|
| 2020 | 1 | Cancer, COVID-19 and The Precautionary Principle: Prioritizing Treatment During A Global Pandemic IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Timothy P Hanna; Gerald A Evans; Christopher M Booth; |
| 2020 | 2 | Improving Cancer Immunotherapy Using Nanomedicines: Progress, Opportunities And Challenges IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Multiple nanotherapeutics have been approved for patients with cancer, but their effects on survival have been modest and, in some examples, less than those of other approved … |
John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain; |
| 2020 | 3 | COVID-19 and Cancer: What We Know So Far IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Peter Sidaway; |
| 2020 | 4 | Provision of Cancer Care During The COVID-19 Pandemic IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
James Spicer; Charlotte Chamberlain; Sophie Papa; |
| 2020 | 5 | Lineage Plasticity in Cancer: A Shared Pathway of Therapeutic Resistance IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Lineage plasticity, the ability of cells to transition from one committed developmental pathway to another, has been proposed as a source of intratumoural heterogeneity and of … |
ÁLVARO QUINTANAL-VILLALONGA et. al. |
| 2020 | 6 | Clinical Development and Potential of Photothermal and Photodynamic Therapies for Cancer IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Light-activated, photosensitizer-based therapies have been established as safe modalities of tumour ablation for numerous cancer indications. Two main approaches are available: … |
Xingshu Li; Jonathan F Lovell; Juyoung Yoon; Xiaoyuan Chen; |
| 2020 | 7 | Current Approaches to The Management of Brain Metastases IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Brain metastases are a very common manifestation of cancer that have historically been approached as a single disease entity given the uniform association with poor clinical … |
JOHN H SUH et. al. |
| 2020 | 8 | The Adenosine Pathway in Immuno-oncology IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit … |
Bertrand Allard; David Allard; Laurence Buisseret; John Stagg; |
| 2020 | 9 | Immunostimulation with Chemotherapy in The Era of Immune Checkpoint Inhibitors IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Conventional chemotherapeutics have been developed into clinically useful agents based on their ability to preferentially kill malignant cells, generally owing to their elevated … |
Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer; |
| 2020 | 10 | Moving Towards Personalized Treatments of Immune-related Adverse Events IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour immune surveillance, but often at … |
KHASHAYAR ESFAHANI et. al. |
| 2019 | 1 | Adverse Effects Of Immune-checkpoint Inhibitors: Epidemiology, Management And Surveillance IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 … |
FILIPE MARTINS et. al. |
| 2019 | 2 | Mechanisms Of Resistance To CAR T Cell Therapy IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell … |
Nirali N Shah; Terry J Fry; |
| 2019 | 3 | Challenges to Curing Primary Brain Tumours IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments … |
KENNETH ALDAPE et. al. |
| 2019 | 4 | Navigating Metabolic Pathways To Enhance Antitumour Immunity And Immunotherapy IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The development of immunotherapies over the past decade has resulted in a paradigm shift in the treatment of cancer. However, the majority of patients do not benefit from … |
XIAOYUN LI et. al. |
| 2019 | 5 | Tumour-associated Neutrophils In Patients With Cancer IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The role and importance of neutrophils in cancer has become increasingly apparent over the past decade. Neutrophils accumulate in the peripheral blood of patients with cancer, … |
Merav E Shaul; Zvi G Fridlender; |
| 2019 | 6 | Comparing And Contrasting Predictive Biomarkers For Immunotherapy And Targeted Therapy Of NSCLC IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-based evidence of molecular pathway and/or oncogene addiction of the … |
D Ross Camidge; Robert C Doebele; Keith M Kerr; |
| 2019 | 7 | Engineering Strategies to Overcome The Current Roadblocks in CAR T Cell Therapy IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: T cells genetically engineered to express chimeric antigen receptors (CARs) have proven – and impressive – therapeutic activity in patients with certain subtypes of B cell … |
Sarwish Rafiq; Christopher S Hackett; Renier J Brentjens; |
| 2019 | 8 | Vessel Co-option In Cancer IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: All solid tumours require a vascular supply in order to progress. Although the ability to induce angiogenesis (new blood vessel growth) has long been regarded as essential to this … |
Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds; |
| 2019 | 9 | The Changing Therapeutic Landscape Of Head And Neck Cancer IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Head and neck cancers are a heterogeneous collection of malignancies of the upper aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the … |
John D Cramer; Barbara Burtness; Quynh Thu Le; Robert L Ferris; |
| 2019 | 10 | Biomarker-guided Therapy for Colorectal Cancer: Strength in Complexity IF:3 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The number of molecularly stratified treatment options available to patients with colorectal cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide … |
Anita Sveen; Scott Kopetz; Ragnhild A Lothe; |
| 2018 | 1 | Targeting The IL-6/JAK/STAT3 Signalling Axis In Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In the tumour … |
Daniel E Johnson; Rachel A O’Keefe; Jennifer R Grandis; |
| 2018 | 2 | Molecular Therapies And Precision Medicine For Hepatocellular Carcinoma IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass an annual incidence of 1 million cases. Genomic studies have established the landscape of … |
Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn; |
| 2018 | 3 | Targeting The PI3K Pathway In Cancer: Are We Making Headway? IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The PI3K-AKT-mTOR pathway is one of the most frequently dysregulated pathways in cancer and, consequently, more than 40 compounds that target key components of this signalling … |
Filip Janku; Timothy A Yap; Funda Meric-Bernstam; |
| 2018 | 4 | Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Immunotherapy has emerged as a major therapeutic modality in oncology. Currently, however, the majority of patients with cancer do not derive benefit from these treatments. … |
Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain; |
| 2018 | 5 | NTRK Fusion-positive Cancers and TRK Inhibitor Therapy IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and … |
Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon; |
| 2018 | 6 | Current State Of Immunotherapy For Glioblastoma IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma. Conventional … |
Michael Lim; Yuanxuan Xia; Chetan Bettegowda; Michael Weller; |
| 2018 | 7 | Targeting The Tumour Stroma To Improve Cancer Therapy IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cancers are not composed merely of cancer cells alone; instead, they are complex ‘ecosystems’ comprising many different cell types and noncellular factors. The tumour stroma is a … |
Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta; |
| 2018 | 8 | Cancer Immunoediting And Resistance To T Cell-based Immunotherapy IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Anticancer immunotherapies involving the use of immune-checkpoint inhibitors or adoptive cellular transfer have emerged as new therapeutic pillars within oncology. These … |
Jake S O’Donnell; Michele W L Teng; Mark J Smyth; |
| 2018 | 9 | State-of-the-art Strategies for Targeting The DNA Damage Response in Cancer IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the … |
Patrick G Pilié; Chad Tang; Gordon B Mills; Timothy A Yap; |
| 2018 | 10 | Hyperprogressive Disease: Recognizing A Novel Pattern To Improve Patient Management IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall survival of a subset of patients across multiple solid tumour types, but other patients can have a … |
STÉPHANE CHAMPIAT et. al. |
| 2017 | 1 | Tumour-associated Macrophages As Treatment Targets In Oncology IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic … |
Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena; |
| 2017 | 2 | Radiomics: The Bridge Between Medical Imaging And Personalized Medicine IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision … |
PHILIPPE LAMBIN et. al. |
| 2017 | 3 | EMT, CSCs, And Drug Resistance: The Mechanistic Link And Clinical Implications IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity – that is, … |
Tsukasa Shibue; Robert A Weinberg; |
| 2017 | 4 | Integrating Liquid Biopsies Into The Management Of Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: During cancer progression and treatment, multiple subclonal populations of tumour cells compete with one another, with selective pressures leading to the emergence of predominant … |
Giulia Siravegna; Silvia Marsoni; Salvatore Siena; Alberto Bardelli; |
| 2017 | 5 | Tumour Heterogeneity And Resistance To Cancer Therapies IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cancer is a dynamic disease. During the course of disease, cancers generally become more heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse … |
Ibiayi Dagogo-Jack; Alice T Shaw; |
| 2017 | 6 | The Immune Contexture In Cancer Prognosis And Treatment IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously … |
Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer; |
| 2017 | 7 | Targeted Agents And Immunotherapies: Optimizing Outcomes In Melanoma IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new … |
Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long; |
| 2017 | 8 | Proteasome Inhibitors In Cancer Therapy IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which … |
Elisabet E Manasanch; Robert Z Orlowski; |
| 2017 | 9 | Cancer Metabolism: A Therapeutic Perspective IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti; |
| 2017 | 10 | Radiotherapy And Immunotherapy: A Beneficial Liaison? IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Investigations into the interaction between radiotherapy and the host immune system have uncovered new mechanisms that can potentially be exploited to improve the efficacy of … |
Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu; |
| 2016 | 1 | Triple-negative Breast Cancer: Challenges And Opportunities Of A Heterogeneous Disease IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of … |
Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni; |
| 2016 | 2 | Safety Profiles Of Anti-CTLA-4 And Anti-PD-1 Antibodies Alone And In Combination IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies has revolutionized … |
CELINE BOUTROS et. al. |
| 2016 | 3 | Treating Cancer With Selective CDK4/6 Inhibitors IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, … |
Ben O’Leary; Richard S Finn; Nicholas C Turner; |
| 2016 | 4 | Imaging Biomarker Roadmap for Cancer Studies IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left … |
JAMES P B O’CONNOR et. al. |
| 2016 | 5 | Cancer Metabolism: A Therapeutic Perspective IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Awareness that the metabolic phenotype of cells within tumours is heterogeneous – and distinct from that of their normal counterparts – is growing. In general, tumour cells … |
Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti; |
| 2016 | 6 | The Future Of Cancer Treatment: Immunomodulation, CARs And Combination Immunotherapy IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok; |
| 2016 | 7 | Driving CAR T-cells Forward IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for … |
Hollie J Jackson; Sarwish Rafiq; Renier J Brentjens; |
| 2016 | 8 | From Tumour Heterogeneity To Advances In Precision Treatment Of Colorectal Cancer IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident. Hence, biomarkers need to be developed that enable the stratification of patients with CRC … |
Cornelis J A Punt; Miriam Koopman; Louis Vermeulen; |
| 2016 | 9 | Genomic Complexity Of Multiple Myeloma And Its Clinical Implications IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant stages, such as monoclonal gammaopathy of undetermined significance and smouldering multiple … |
SALOMON MANIER et. al. |
| 2016 | 10 | Counselling Framework For Moderate-penetrance Cancer-susceptibility Mutations IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The use of multigene panels for the assessment of cancer susceptibility is expanding rapidly in clinical practice, particularly in the USA, despite concerns regarding the … |
NADINE TUNG et. al. |
| 2015 | 1 | Targeting Notch, Hedgehog, And Wnt Pathways In Cancer Stem Cells: Clinical Update IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: During the past decade, cancer stem cells (CSCs) have been increasingly identified in many malignancies. Although the origin and plasticity of these cells remain controversial, … |
NAOKO TAKEBE et. al. |
| 2015 | 2 | Inflammation And Cancer: Advances And New Agents IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Tumour-promoting inflammation is considered one of the enabling characteristics of cancer development. Chronic inflammatory disease increases the risk of some cancers, and strong … |
Shanthini M Crusz; Frances R Balkwill; |
| 2015 | 3 | Combination Cancer Immunotherapies Tailored To The Tumour Microenvironment IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan for many patients with many cancer types in the near future. There are many … |
Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng; |
| 2015 | 4 | Pancreatic Cancer: From State-of-the-art Treatments To Promising Novel Therapies IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased … |
Ignacio Garrido-Laguna; Manuel Hidalgo; |
| 2015 | 5 | Clinical Relevance Of Host Immunity In Breast Cancer: From TILs To The Clinic IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The clinical relevance of the host immune system in breast cancer has long been unexplored. Studies developed over the past decade have highlighted the biological heterogeneity of … |
PETER SAVAS et. al. |
| 2015 | 6 | Advances In Targeted Therapies For Hepatocellular Carcinoma In The Genomic Era IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Josep M Llovet; Augusto Villanueva; Anja Lachenmayer; Richard S Finn; |
| 2015 | 7 | Clinical Management Of Breast Cancer Heterogeneity IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of different histological subtypes, treatment sensitivity profiles, and clinical outcomes … |
Dimitrios Zardavas; Alexandre Irrthum; Charles Swanton; Martine Piccart; |
| 2015 | 8 | Exploiting The Critical Perioperative Period To Improve Long-term Cancer Outcomes IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Evidence suggests that the perioperative period and the excision of the primary tumour can promote the development of metastases—the main cause of cancer-related mortality. This … |
Maya Horowitz; Elad Neeman; Eran Sharon; Shamgar Ben-Eliyahu; |
| 2015 | 9 | Novel Immunotherapies In Lymphoid Malignancies IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid malignancies provided proof-of-principle for exploiting the immune system therapeutically. … |
Connie Lee Batlevi; Eri Matsuki; Renier J Brentjens; Anas Younes; |
| 2015 | 10 | Refining The Treatment Of NSCLC According To Histological And Molecular Subtypes IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into subtypes based on genotype and histology has resulted in dramatic improvements in disease … |
Anish Thomas; Stephen V Liu; Deepa S Subramaniam; Giuseppe Giaccone; |
| 2014 | 1 | Clinical Relevance Of Circulating Cell-free MicroRNAs In Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Efficient patient management relies on early diagnosis of disease and monitoring of treatment. In this regard, much effort has been made to find informative, blood-based … |
Heidi Schwarzenbach; Naohiro Nishida; George A Calin; Klaus Pantel; |
| 2014 | 2 | Acquired Resistance To TKIs In Solid Tumours: Learning From Lung Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The use of advanced molecular profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung … |
D Ross Camidge; William Pao; Lecia V Sequist; |
| 2014 | 3 | Therapeutic Vaccines For Cancer: An Overview Of Clinical Trials IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting … |
IGNACIO MELERO et. al. |
| 2014 | 4 | The Clinical Development Of MEK Inhibitors IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Aberrant activation of the RAS-RAF-MEK-ERK1/2 pathway occurs in more than 30% of human cancers. As part of this pathway, MEK1 and MEK2 have crucial roles in tumorigenesis, cell … |
Yujie Zhao; Alex A Adjei; |
| 2014 | 5 | Standing The Test Of Time: Targeting Thymidylate Biosynthesis In Cancer Therapy IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Over the past 60 years, chemotherapeutic agents that target thymidylate biosynthesis and the enzyme thymidylate synthase (TS) have remained among the most-successful drugs used in … |
Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner; |
| 2014 | 6 | Metronomics: Towards Personalized Chemotherapy? IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Since its inception in 2000, metronomic chemotherapy has undergone major advances as an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy and its … |
Nicolas André; Manon Carré; Eddy Pasquier; |
| 2014 | 7 | Emerging Biomarkers In Head And Neck Cancer In The Era Of Genomics IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Head and neck cancer (HNC) broadly includes carcinomas arising from the mucosal epithelia of the head and neck region as well as various cell types of salivary glands and the … |
Hyunseok Kang; Ana Kiess; Christine H Chung; |
| 2014 | 8 | Mechanisms Of Neuroblastoma Regression IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Recent genomic and biological studies of neuroblastoma have shed light on the dramatic heterogeneity in the clinical behaviour of this disease, which spans from spontaneous … |
Garrett M Brodeur; Rochelle Bagatell; |
| 2014 | 9 | Current Approaches To The Treatment Of Metastatic Brain Tumours IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Metastatic tumours involving the brain overshadow primary brain neoplasms in frequency and are an important complication in the overall management of many cancers. Importantly, … |
TAOFEEK K OWONIKOKO et. al. |
| 2014 | 10 | Treatment Of Intermediate-stage Hepatocellular Carcinoma IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Hepatocellular carcinoma (HCC)-closely associated with liver cirrhosis and, in fact, the main cause of death in patients with such disease-is now recognized as one of the … |
Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul; |
| 2013 | 1 | Liquid Biopsy: Monitoring Cancer-genetics In The Blood IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations is increasingly used for diagnostic, prognostic and treatment purposes. The genetic … |
Emily Crowley; Federica Di Nicolantonio; Fotios Loupakis; Alberto Bardelli; |
| 2013 | 2 | Image-guided Cancer Surgery Using Near-infrared Fluorescence IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Paradigm shifts in surgery arise when surgeons are empowered to perform surgery faster, better and less expensively than current standards. Optical imaging that exploits invisible … |
Alexander L Vahrmeijer; Merlijn Hutteman; Joost R van der Vorst; Cornelis J H van de Velde; John V Frangioni; |
| 2013 | 3 | Development Of PI3K Inhibitors: Lessons Learned From Early Clinical Trials IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The phosphatidylinositol 3-kinase (PI3K) pathway has an important role in cell metabolism, growth, migration, survival and angiogenesis. Drug development aimed at targetable … |
Jordi Rodon; Rodrigo Dienstmann; Violeta Serra; Josep Tabernero; |
| 2013 | 4 | Latest Research And Treatment Of Advanced-stage Epithelial Ovarian Cancer IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics, despite prolific … |
Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog; |
| 2013 | 5 | Treating B-cell Cancer With T Cells Expressing Anti-CD19 Chimeric Antigen Receptors IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Most B-cell malignancies express CD19, and a majority of patients with B-cell malignancies are not cured by current standard therapies. Chimeric antigen receptors (CARs) are … |
James N Kochenderfer; Steven A Rosenberg; |
| 2013 | 6 | Breathing New Life Into Immunotherapy: Review Of Melanoma, Lung And Kidney Cancer IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving … |
Charles G Drake; Evan J Lipson; Julie R Brahmer; |
| 2013 | 7 | The Society For Immunotherapy Of Cancer Consensus Statement On Tumour Immunotherapy For The Treatment Of Cutaneous Melanoma IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of … |
HOWARD L KAUFMAN et. al. |
| 2013 | 8 | Emerging Targeted Agents In Metastatic Breast Cancer IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Extensive preclinical experimentation has conceptually changed the way we perceive breast cancer, with the wide spectrum of genomic alterations governing its malignant progression … |
Dimitrios Zardavas; José Baselga; Martine Piccart; |
| 2013 | 9 | Treatment-related Cardiotoxicity In Survivors Of Childhood Cancer IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Treatment advances and higher participation rates in clinical trials have rapidly increased the number of survivors of childhood cancer. However, chemotherapy and radiation … |
Steven E Lipshultz; Thomas R Cochran; Vivian I Franco; Tracie L Miller; |
| 2013 | 10 | Circulating Tumour Cells And Cell-free DNA As Tools For Managing Breast Cancer IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Circulating blood biomarkers promise to become non-invasive real-time surrogates for tumour tissue-based biomarkers. Circulating biomarkers have been investigated as tools for … |
LETICIA DE MATTOS-ARRUDA et. al. |
| 2012 | 1 | Patient-derived Tumour Xenografts As Models For Oncology Drug Development IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort … |
JOHN J TENTLER et. al. |
| 2012 | 2 | Understanding The Mechanisms And Treatment Options In Cancer Cachexia IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cancer cachexia is a metabolic syndrome that can be present even in the absence of weight loss (‘precachexia’). Cachexia is often compounded by pre-existing muscle loss, and is … |
Kenneth Fearon; Jann Arends; Vickie Baracos; |
| 2012 | 3 | The Role Of Aspirin In Cancer Prevention IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding. … |
Michael J Thun; Eric J Jacobs; Carlo Patrono; |
| 2012 | 4 | Imaging Hypoxia To Improve Radiotherapy Outcome IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Reduced oxygen levels (hypoxia) is one of the most important factors influencing clinical outcome after radiotherapy. This is primarily because hypoxic cells are resistant to … |
Michael R Horsman; Lise Saksø Mortensen; Jørgen B Petersen; Morten Busk; Jens Overgaard; |
| 2012 | 5 | The European LeukemiaNet AML Working Party Consensus Statement On Allogeneic HSCT For Patients With AML In Remission: An Integrated-risk Adapted Approach IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or … |
JAN J CORNELISSEN et. al. |
| 2012 | 6 | Dynamic Contrast-enhanced MRI In Clinical Trials Of Antivascular Therapies IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: About 100 early-phase clinical trials and investigator-led studies of targeted antivascular therapies–both anti-angiogenic and vascular-targeting agents–have reported data … |
James P B O’Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson; |
| 2012 | 7 | MET: A Promising Anticancer Therapeutic Target IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with … |
Solange Peters; Alex A Adjei; |
| 2012 | 8 | Diagnostic And Therapeutic Avenues For Glioblastoma: No Longer A Dead End? IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Glioblastomas are heterogeneous neoplasms that are driven by complex signalling pathways, and are among the most aggressive and challenging cancers to treat. Despite standard … |
Shota Tanaka; David N Louis; William T Curry; Tracy T Batchelor; Jorg Dietrich; |
| 2012 | 9 | Image-guided Radiotherapy: From Current Concept To Future Perspectives IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Radiotherapy is a highly effective, targeted therapy for the management of cancer. Technological innovations have enabled the direct integration of imaging technology into the … |
David A Jaffray; |
| 2012 | 10 | Cancer Prevention By Targeting Angiogenesis IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Healthy individuals can harbour microscopic tumours and dysplastic foci in different organs in an undetectable and asymptomatic state for many years. These lesions do not progress … |
Adriana Albini; Francesca Tosetti; Vincent W Li; Douglas M Noonan; William W Li; |
| 2011 | 1 | Treatment Of HER2-positive Breast Cancer: Current Status And Future Perspectives IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these … |
CARLOS L ARTEAGA et. al. |
| 2011 | 2 | Autophagy As A Target For Anticancer Therapy IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Autophagy is an important homeostatic cellular recycling mechanism responsible for degrading unnecessary or dysfunctional cellular organelles and proteins in all living cells. … |
Filip Janku; David J McConkey; David S Hong; Razelle Kurzrock; |
| 2011 | 3 | Antiangiogenic Therapy: Impact On Invasion, Disease Progression, And Metastasis IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease progression in some patients, leading to progression-free survival (PFS) and overall survival … |
John M L Ebos; Robert S Kerbel; |
| 2011 | 4 | Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Medicine will move from a reactive to a proactive discipline over the next decade–a discipline that is predictive, personalized, preventive and participatory (P4). P4 medicine … |
Leroy Hood; Stephen H Friend; |
| 2011 | 5 | Immune Parameters Affecting The Efficacy Of Chemotherapeutic Regimens IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells by causing them to elicit an immune response or … |
Laurence Zitvogel; Oliver Kepp; Guido Kroemer; |
| 2011 | 6 | Oligometastases Revisited IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: We previously proposed a clinical state of metastasis termed ‘oligometastases’ that refers to restricted tumor metastatic capacity. The implication of this concept is that local … |
Ralph R Weichselbaum; Samuel Hellman; |
| 2011 | 7 | Noninvasive Cell-tracking Methods IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cell-based therapies, such as adoptive immunotherapy and stem-cell therapy, have received considerable attention as novel therapeutics in oncological research and clinical … |
Moritz F Kircher; Sanjiv S Gambhir; Jan Grimm; |
| 2011 | 8 | HCC And Angiogenesis: Possible Targets And Future Directions IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs … |
Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain; |
| 2011 | 9 | Treatment Of Multiple Myeloma IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The treatment of multiple myeloma has changed dramatically in the past decade. The increase in the number of active agents has generated numerous possible drug combinations that … |
S Vincent Rajkumar; |
| 2011 | 10 | Predictive Biomarkers: A Paradigm Shift Towards Personalized Cancer Medicine IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Advances in our understanding of the intricate molecular mechanisms for transformation of a normal cell to a cancer cell, and the aberrant control of complementary pathways, have … |
Nicholas B La Thangue; David J Kerr; |
| 2010 | 1 | Delivering Nanomedicine To Solid Tumors IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Recent advances in nanotechnology have offered new hope for cancer detection, prevention, and treatment. While the enhanced permeability and retention effect has served as a key … |
Rakesh K Jain; Triantafyllos Stylianopoulos; |
| 2010 | 2 | Targeting Cancer Stem Cells By Inhibiting Wnt, Notch, And Hedgehog Pathways IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Tumor relapse and metastasis remain major obstacles for improving overall cancer survival, which may be due at least in part to the existence of cancer stem cells (CSCs). CSCs are … |
Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy; |
| 2010 | 3 | Advanced Pancreatic Carcinoma: Current Treatment And Future Challenges IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading cause of cancer-related death in North America. Most patients present with locally advanced … |
Anastasios Stathis; Malcolm J Moore; |
| 2010 | 4 | Triple-negative Breast Cancer: Disease Entity Or Title Of Convenience? IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: This Review outlines the understanding and management of triple-negative breast cancer (TNBC). TNBC shares morphological and genetic abnormalities with basal-like breast cancer … |
Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni; |
| 2010 | 5 | Metronomic Chemotherapy: New Rationale For New Directions IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Tumor angiogenesis is recognized as a major therapeutic target in the fight against cancer. The key involvement of angiogenesis in tumor growth and metastasis has started to … |
Eddy Pasquier; Maria Kavallaris; Nicolas André; |
| 2010 | 6 | Translating P53 Into The Clinic IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other 50% of cases, the TP53 gene itself is not mutated but the p53 pathway is often partially … |
Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane; |
| 2010 | 7 | MTOR Signaling And Drug Development In Cancer IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Mammalian target of rapamycin (mTOR) is a protein kinase of the PI3K/Akt signaling pathway. Activation of mTOR in response to growth, nutrient and energy signals leads to an … |
Janet Dancey; |
| 2010 | 8 | Drug Resistance In Metastatic Castration-resistant Prostate Cancer IF:5 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Docetaxel in combination with prednisone is the standard of care in men with symptomatic castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with … |
Bostjan Seruga; Alberto Ocana; Ian F Tannock; |
| 2010 | 9 | Metastamirs: A Stepping Stone Towards Improved Cancer Management IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: MicroRNAs (miRNAs) are non-coding RNAs that regulate protein expression. Aberrant miRNA expression in cancer has been well documented; miRNAs can act as oncogenes or … |
NICOLE M A WHITE et. al. |
| 2010 | 10 | Mismatch Repair Deficient Colorectal Cancer In The Era Of Personalized Treatment IF:4 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The molecular and genetic subtyping of cancer has allowed the emergence of individualized therapies. This approach could potentially deliver treatments that have both increased … |
Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth; |